Physician profile
Aaron C Cunningham
NPI 1508190695
$1,394.41
in general payments reported to CMS, 2019-2025
13 companies · $1,175 in 2025
The $1,175 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.90 · 2023: $137 · 2024: $64.20 · 2025: $1,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,226 · Education: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,225.52 |
| Education | $150.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $317.93 | 2025 | Fasenra, Airsupra |
| Astellas Pharma US INC | $269.50 | 2022-2025 | Cresemba |
| Glaxosmithkline, LLC. | $163.91 | 2024-2025 | Nucala, Trelegy Ellipta |
| Boston Scientific Corporation | $123.61 | 2023 | Resolution 360 Clip |
| Verona Pharma, INC. | $105.29 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.95 | 2024-2025 | Ofev |
| United Therapeutics Corporation | $76.27 | 2025 | Tyvaso, Steen Solution |
| Takeda Pharmaceuticals U.S.A., INC. | $68.33 | 2025 | Livtencity, Aralast |
| Genentech USA, INC. | $55.02 | 2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $47.77 | 2025 | Dupixent |
| Genzyme Corporation | $30.14 | 2025 | |
| Scpharmaceuticals INC. | $27.81 | 2024 | |
| Celgene Corporation | $13.88 | 2023 | Pomalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.